STCube Submits Clinical Phase 1 Trial Plan for Immuno-Oncology Drug to US FDA
[Asia Economy Reporter Minji Lee] STCube announced on the 20th that it has applied to the US FDA for a Phase 1, multicenter open-label clinical trial plan to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hsTC810 monotherapy in patients with advanced solid tumors.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "hsTC810 is a multinational clinical trial, and after applying for clinical trials with the Korea Food and Drug Administration, we additionally applied for clinical trials with the US FDA," adding, "We plan to disclose the information according to disclosure guidelines upon approval of the clinical trial plans by the MFDS and FDA."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
